This article reviews the current status of classes of HIV-1 integrase enzyme inhibitors. These classes include peptide-based inhibitors, natural products, polyhydroxylated aromatics, diketo acids, naphthyridines, and sulfonated compounds including sulfonic acids. Discussions of structure activity relationships are presented and include the current overview of the structure-based model, suitable for the further design and development. To date, the advances in the medicinal chemistry of HIV-1 integrase inhibitors have relied mostly on ligand-based designs leading to most displaying similar binding interactions within the active site or at the dimer interface. This paves the way for single enzyme mutations rendering entire compound classes inactive and thus, the requirement for second and third generation inhibitors with novel modes of binding is apparent. To facilitate future structure-based drug design efforts, a model of the biologically relevant structure of the HIV-1 integrase enzyme, a dimmer of dimmers has also been discussed. 
Introduction
The human immunodeficiency virus (HIV), first identified in 1983, is commonly accepted as the causative agent of acquired immunodeficiency syndrome (AIDS) [1] . The prognosis of AIDS patients who have full access to current therapies has dramatically changed since the first cases of AIDS were reported. Prior to the inception of the first anti-HIV drug, AZT [2, 3] , in 1987 the life expectancy for AIDS patients was less than 1 year, whereas today the median survival for HIV-positive patients receiving treatment exceeds 8 years [4] . Moreover, the median survival for patients prescribed current combination therapies has not been determined, as these were only introduced 8 years ago. This dramatic change is due to the development of effective therapies, to early detection of HIV-positive individuals, and a sustained effort to analyse and understand viral resistance mechanisms, which can be overcome by rational drug development and combination therapy [4] .
At present, triple therapy, or highly active antiretroviral therapy (HAART), is the standard treatment for infection. HAART typically consists of a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor (NNRTI) in combination with two nucleoside reverse transcriptase inhibitors (NRTI) [5] [6] [7] [8] [9] [10] . These multi-drug combination regimens have made it possible to suppress the replication of HIV to such an extent that the virus becomes undetectable in infected individuals.
Unfortunately, HAART requires patients to adhere to long-term complicated dosing regimens resulting in many patients becoming non-compliant.
Despite rapid advances in the treatment of HIV infection, eradication of the virus has failed due to the persistence of latent HIV-1 in resting memory CD4 + T cells [11] [12] [13] [14] [15] [16] . Furthermore, the emergence of HIV strains resistant to antiretroviral drugs aimed at any of the aforementioned viral targets is an inevitable phenomenon. Thus, there is a clear and present need to develop new therapies, which target alternative steps in the viral cycle.
HIV-1 Integrase as a Potential Target for Antiviral Therapy
An important, yet unexploited potential therapeutic target is the HIV-1 integrase enzyme (IN). IN is a particularly attractive antiviral target as it is indispensable in the HIV lifecycle and perhaps more importantly it has no cellular counterparts indicating that specific and non-toxic inhibitors could be developed [17] .
The genome of this retrovirus is encoded as RNA and during the viral lifecycle, after translation into DNA (by reverse transcriptase), it needs to be integrated into the host genome -this is facilitated by IN. Specifically, it catalyses two distinct reactions, these being 3 -processing and strand transfer.
During 3 -processing, which occurs in the cytoplasm of the infected cell, the enzyme catalyses the resection of a 5 -GT dinucleotide from each end of the viral DNA thereby generating the nucleophilic 3 -hydroxyl ends required for strand transfer [18] [19] [20] . This water-mediated endonucleolytic cleavage of the 5 -GT dinucleotides occurs immediately 3 to a highly conserved CA dinucleotide, any alteration of this sequence prevents IN from catalysing 3 -processing [21] [22] [23] .
Following 3 -processing, integrase undergoes a structural change in preparation for the binding of the acceptor (chromosomal) DNA [24, 25] . IN, still bound to the 3'-processed viral DNA, translocates to the nucleus of the infected cell as a part of a pre-integration complex (PIC), wherein the terminal 3'-OH of the viral DNA attacks the host DNA [26] [27] [28] [29] . Strand transfer is coordinated in such a way that each of the 3 -hydroxyl ends attack a DNA phosphodiester bond on each strand of the chromosomal DNA with a five-base-pair stagger across the DNA major groove [4, 30, 31] . This leaves a five-base single-stranded gap at each junction between the integrated viral DNA and chromosomal DNA, and a two-base flap at the 5 -ends of the viral DNA, which are repaired by cellular DNA repair enzymes [4] .
HIV IN Structure and Functional Domains
HIV-1 IN is a 32-kDa protein, composed of 288 amino acids. When dissecting the molecular structure of the HIV-1 IN, three discrete domains can be distinguished, the amino-terminal domain (NTD), the catalytic core domain (CCD) and the carboxyl terminal domain (CTD).
The NTD encompasses residues 1-50 and has been shown to interact with DNA as part of the IN complex but does not exhibit DNA binding properties when isolated in solution [32] [33] [34] . In keeping with integrases of retroviruses, retrotransposons, and even many prokaryotic transposable elements, the NTD contains a histidine-histidine-cysteine-cysteine motif (HHCC) to which Zn 2+ binds in a 1:1 stoichiometry [35] [36] [37] . The domain comprises a four -helix bundle which forms a dimer in solution.
The domains are stabilised by a hydrophobic region and the zinc binding motif, consequently the mutation of a single residue within the HHCC results in the domain losing structure and DNA binding ability [32, 37] .
The catalytic core is structurally remarkably similar to other retroviral integrases and retrotransposons [38] . This family of DNA-processing enzymes typically contain a canonical Asp, Asp, Glu motif, which in HIV-1 IN is formed by Asp-64, Asp-116 and Glu-152, with the two aspartic acid residues forming a coordination complex with a divalent metal [39] [40] [41] [42] . Although it is well accepted that a metal co-factor is required for catalysis, to date no definitive conclusions have been reached regarding the type, Mg 2+ of Mn 2+ , or number of metal ions required [43, 44] . However, it is generally accepted that Mg 2+ is a more likely cofactor given its one million-fold abundance over Mn 2+ in cells [45, 46] . Further although the X-ray structures show one metal ion within the active site, it is believed that the second metal ion comes with DNA potentially coordinating with the carboxylate oxygen atoms of Glu-152 and possibly Asp-64 [43] .
The C-terminal domain is primarily composed of -strands and is the least conserved domain among the retroviral integrases [40, [47] [48] [49] . The isolated C-terminal domain has been shown to bind DNA in a nonspecific manner and also dimerises when isolated in solution [40] . In addition, this domain has been implicated in protein-protein interactions [50] as it has been shown to interact with RT, an interaction which appears to be crucial for RT catalytic activity [51, 52] .
At present, crystal structures of the NTD [35, 36] , CCD [53, 39, 40, 38, [54] [55] [56] [57] [58] , CTD [48, 49] , as well as the CCD with the NTD [59] , and the CCD with the CTD [39] , have been reported. However, crystallisation of the entire enzyme has proven to be difficult and to date no complete X-ray crystal structure has been reported. Consequently, the relative spatial arrangement of these structural domains, and their interactions with DNA substrates has remained largely unknown. However, as illustrated in figure 1 , it appears as if the enzyme adopts at least a dimeric conformation in which the active sites of the opposing units are on opposite sides of the complex. As shown in figure 1, this dimerisation is mediated by a number of hydrophobic interactions between various secondary structures found at the dimeric interface, such as alpha helices 1, 3, 5, 6 and beta-strand 3 [60] . Figure 1 , (a) and (b) -ribbon and cartoon representations: Dimerisation of the core domains is mediated by a number of hydrophobic interactions. The primary interactions are between alpha helices 1, 3, 6 and beta-strand 3 which are coloured red, yellow, dark blue, and light blue respectively. The active-site Mg 2+ ion and co-crystallised water molecules are coloured by atom type (PBD code 1QS4). The residues of the catalytic triad are represented as sticks and coloured by atom type. The core domain adopts a dimeric formation in which the active-sites of the opposing domains are on opposite faces of the complex. (c) and (d): The CCDs (dark-blue) of the two units directly involved in catalysis encapsulate the chromosomal DNA (light-blue) while their NTDs (red) appear to play a crucial role in the binding and positioning of the chromosomal DNA [61] . Further the CTDs (yellow) of two catalytically involved units appear to play a dual role binding the viral and chromosomal DNA, while the NTDs (green) and CTDs (black) of the two units not directly involved in catalysis appear to assist in the binding and positioning of the viral DNA (yellow). (d) Additional view: 'Sliced in half' and rotated 90°C to the right.
In a recently published model (Figure 1 , (c) and (d)), it has been proposed that a dimer of dimers is required for activity [61] . In this model only two complete IN units, one from each dimer, are directly involved in catalysis, while the other two units provide structural support to the complex and participate in the binding of the viral DNA [61] . As illustrated in figure 1 (c) and (d), the CCDs (darkblue) of the two units directly involved in catalysis encapsulate the chromosomal DNA (light-blue) while their NTDs (red) appear to play a crucial role in the binding and positioning of the chromosomal DNA. Further, the CTDs (yellow) of two catalytically involved units appear to play a dual role binding the viral and chromosomal DNA, while the NTDs (green) and CTDs (black) of the two units not directly involved in catalysis appear to assist in the binding and positioning of the viral DNA (yellow) [61] .
HIV-1 Integrase Inhibitors
In contrast to RT and PR, the paucity of structural information has hampered structure-based discovery of selective inhibitors targeted to IN. As a consequence, many groups have turned to substrate-based drug design and high-through screening of chemical or natural product libraries to search for novel lead molecules. Such studies have unearthed a plethora of inhibitors based on diverse scaffolds including substrate-based inhibitors, numerous natural products, polyhydroxylated aromatics, aryl--diketoacids, naphthyridines, styrylquinolines, a number of peptides, and sulfur based analogues.
Substrate-Based IN Inhibitors
Rational design commonly begins with the investigation of compounds that are based on, or mimic the natural enzyme substrate. Amongst the first substrate-based HIV-1 IN inhibitors reported were the dinucleotides 5'-pGT-3' (1, Table 1), which is excised from the 3 -end of the viral DNA during 3 -processing, and 5'pCA-3' (2, Table 1), which is immediately upstream [62] . Upon further investigation three other dinucleotides, 5'pCT-3', 5'-pAC-3', and 5'-pAT-3' (3-5, respectively, Table   1 ) were also identified as potent inhibitors of IN [62] . 
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Non-Natural Natural Figure 2 : Structure and activity of the natural substrate-based inhibitor 4, the non-natural derivative 6, and the isodeoxyuracil derivative 7 against 3 -processing (3 P) and strand transfer (ST). A number of oligonucleotides have also been identified as potent IN inhibitors [66] , however to date the most potent oligonucleotides reported were a series of analogues composed entirely from deoxyguanosine and thymidine, known as guanosine quartets [67] . However, these quartets are not only IN inhibitors, as their primary viral target is gp120. Nevertheless, compound 8 (Zintevir) [67] is currently in pre-clinical trials.
Small-Molecule Natural Product IN Inhibitors
Over the past several years, a plethora of compounds isolated from natural sources have been identified as HIV-1 IN inhibitors. As illustrated in figure 4 , amongst the first identified were aurintricarboxylic acid (9) [68] , the Fusarium heterosporum isolate equisetin (10) [69] , integric acid (11) [70] from Xylaria sp., several lichen acids of the depside and depsidone families, such as chloroparellic acid (12) [71] and stictic acid (13) [71] , and a number of lignanolides, exemplified byconidendrol (14) [72] . Others include many tetracyclins, such as the DNA binder doxorubicin (15) [73], antioxidants such as flavones, and a number of compounds isolated from food stuffs such as curcumin (16) [74] , which was isolated from the widely used spice cumin. Clearly, numerous naturally occurring compounds based on extremely diverse scaffolds display inhibitory effects against HIV-1 IN. Thus, elucidation of the common essential structural and chemical features required for activity is an extremely onerous task. As a result, many groups have adopted molecular modelling approaches, such as pharmocophore generation, to determine important threedimensional arrangements and essential functional groups needed to effectively interact with the enzyme [81] [82] [83] [84] [85] [86] [87] [88] [89] . However, a consistent theme in a significant number of natural product IN inhibitors is the presence of polyhydroxylated aromatic moieties. Consequently, a significant amount of research has focused on identifying and subsequently modifying polyphenolic IN inhibitors.
Polyhydroxylated Aromatic HIV-1 Inhibitors
The group of polyhydroxylated aromatics (PHAs) embodies the most numerous and diverse class of HIV IN inhibitors. As illustrated in figure 6 , the majority of the PHAs share a common architecture consisting of two aryl units, one of which contains the 1,2-catechol pattern, separated by a linker segment. Examples of the class include flavones such as quercetagetin (26) [90] , caffeic acid phenethyl ester analogues (CAPE) (27) [90] , and chicoric acids (28) [91, 92] . (26), CAPE (27) , and L-chicoric acid (28) . The majority of the PHAs share a common architecture consisting of two aryl units, one of which contains the 1,2-catechol pattern, separated by a linker segment.
To date no definitive conclusions regarding the inhibitory action of the PHAs have been reported.
It is unclear whether the hydroxyl moieties act by chelating the active-site magnesium ions or are simply involved in hydrogen bonding within the catalytic core. However, a co-crystallised structure of the enzyme core with the catechol-containing 30 ( Figure 7 ) [57] , suggests that the PHAs may elicit their inhibitory effects by causing steric obstruction at the dimer interface, possibly leading to an arrest in the formation of an enzymatically functional multimeric complex. Unfortunately the precise binding mode of 30 is unclear as the ligand in this structure is only partially resolved. PBD code 1HYV 57 ; core domain, grey) on the core domain backbone co-crystallised with 30 (PBD code 1HYZ 57 ; black). It has been proposed that the binding of 30 induces a number of conformational changes to a number of key active-site residues while binding of 29 does not induce any conformational changes [57] . However, superimposition of the two structures reveals no significant conformational changes to any key active-site residues (active-site residues of both 1HYV and 1HYZ are represented as sticks).
Although a plethora of PHAs have been identified as potent in vitro IN inhibitors [93] [94] [95] , the in vivo antiviral effects of a significant number of PHAs can be attributed to non-integrase-dependent phenomena. For example, the primary antiviral target of the L-chicoric acid analogues is the viral envelope glycoprotein gp120 [96] . Furthermore, a large portion of the PHAs are cytotoxic which is believed to result from non-selective binding and, perhaps more importantly, from the formation of oxidised species, such as semiquinones or orthoquinones, which form protein or possibly DNA adducts [97, 98] .
In an attempt to separate the mechanism of cytotoxicity and IN inhibition a number of monohydroxylated [95] derivatives as well as methoxy (31, Figure 8 ) [95] and acetyl protected catechol analogues [99] were produced, none of which exhibited a significant inhibitory response. Further, as illustrated by 33 and 34 [93] , which were designed to mimic the two distinct rotational isomers of CAPE, it appears that subtle conformational factors play a significant role in inhibitor binding. This indicates the Achilles' heal of the PHAs is the absolute requirement of a catechol moiety. The structure and activity of 31 and 32 illustrating the dramatic reduction in activities resulting from the protection of the catachol moieties. Further the structure and activity of 33 and 34, which were designed to mimic the two distinct rotational isomers of CAPE indicating that subtle conformational factors play a significant role in inhibitor binding.
In an order to identify novel PHA inhibitors devoid of the critical catechol functionality a ligand based molecular modelling approach was adopted from which a number of novel salicylhydrazides were identified as IN inhibitors (35 & 36, Figure 9 ) [100] . A structure-activity relationship (SAR) study of the lead compounds indicated that the two 2-hydroxy moieties may mimic a catechol as the removal of one or both moieties [100] , or separation of the hydroxyls via chain extension of the hydrazine linker yielded inactive compounds [100] . To investigate the potential binding mode of these compounds three mercaptosalicylhydrazide compounds (MSHs), 37, 38, and 39 were designed and synthesised. The MSHs were found to be 300-fold less cytotoxic and exhibited antiviral activity. Further site-directed mutagensis and molecular modelling studies indicated that the MSHs bind to Cys-65, located in the active-site, and chelate Mg 2+ [100] . The structure and activity of the salicylhydrazides 35 and 36 identified during a pharmacophore study [100] and the mercaptosalicylhydrazide compounds (MSHs) 37-39 synthesised in an ensuing SAR study [100] . [101] . Further, a photoaffinity study, which utilised a number of coumarins possessing a photo-activatable benzophenone moiety, indicated that binding occurred at the core dimer interface [102] . suggesting the coumarins exhibit their inhibitory effects by causing a steric obstruction of the dimer complex [102] .
Despite the enormous number of PHA IN inhibitors identified, only a handful of patents have been filed. To date, the only patented PHAs are the chicoric acids [96] , 3,5-dicaffeoylquinic acids [103] , and caffeoyl naphthalenesulfonamides [99] . Two other patented compounds are an amino acid derivative [95] and the non-viral entry inhibitor lithospermic acid [95] , isolated from Salvia miltiorrhiza. However, all of these compounds have failed to reach clinical trials, presumably due to poor cellular uptake and non-specific inhibition. Nevertheless, the development of a therapeutically viable PHA remains an attractive proposition as it is envisaged that a diet rich in natural PHAs such as chicoric acids and lithospermic acids, commonly found in vegetables such as lettuce, may reduce therapeutic doses [104] . [107] , were independently identified by both the Merck and Shionogi companies [108] [109] [110] . [108] [109] [110] Although the diketo functionality, which is believed to chelate two magnesium ions [111] , is an intrinsic feature of the DKAs it is not sufficient for activity. As typified by compound 46 [112] (Figure   12b ) which appears to be the minimum scaffold required for activity, DKAs require an aryl portion and an acid portion. A member of the DKA family, 5CITEP (47, Figure 12a ) [54] , was subsequently cocrystallised with the enzyme catalytic core providing the first X-ray crystal structure of an inhibitor in complex with the active-site [54] . The co-crystal structure of the core with 5CITEP [54] indicates the carboxylic acid, or in the case of 5CITEP the carboxylic mimic tetrazole, occupies the phosphate bind-pocket forming interactions with Lys-156 and Lys-159, whilst the aryl portion occupies a hydrophobic region of the active-site. However, the 5CITEP co-crystallised crystal structure disclosed minimal interactions between the ligand and the resolved Mg 2+ .
In general, the DKAs are characterised by an ability to afford preferential inhibition of strand transfer (ST) versus 3-processing (3'-P). The high selectivity for the strand-transfer reaction indicates that the DKAs bind to the enzyme following 3'-processing [4] . This inhibitory response is generally Figure 13 ). However, as illustrated by 50 [116] , the size of these substituents appears to be limited and if hydrophilic substituents are introduced selective inhibition of strand-transfer is removed 51 [117] suggesting such analogues may elicit there inhibitory response via a slightly different mechanism. Slight improvements in the antiviral activity of the mono-substituted variants, exemplified by 52 [118] (Figure 14) , can be gained with the introduction of a halogen atom at the 2'-position on the distal benzene ring, while halogen introduction at the 3'-position and the 4'-position leads to no increase or a significant loss in activity respectively [118] . Further, slight increases in whole cell activity can be achieved with the introduction of small substituents such as methoxy (53, Figure 14 ) [118] , ethoxy, and isopropoxy at the 2-position [117, 118] .
Although it is established that substituents at the 3, Figure 15 ) [112] . Moreover, while a number of the indole derivatives exhibited potent in vitro activity, the majority displayed limited antiviral activity and the select few analogues displaying in vivo inhibition (e.g. 56 Figure 15 ) [112, 120] were cytotoxic. In keeping with the indole DKAs, purine (57 & 58, Figure 16 ) 121 and pyrimidine (59 & 60) [122] analogues displayed potent in vitro activity, reduced in vivo activity and reduced strand-transfer selectivity. However, the reduction of selectivity of these analogues is not expected as they mimic the natural substrate. It is apparent that the subsitituent orientation relative to the diketo acid functionality is significant.
As illustrated by compounds 61 to 65 [118] , (Figure 17 ) potency increases as the angle between the two lines extending from the benzyl and diketoacid moiety increases from 60°to 120°and decreases as the angle exceeds 120°. In contrast to the aryl portion of the DKAs, the central diketo moiety has received considerably less attention with the only major study investigating the effect of elongating the diketo group from a 2,4-dioxobutanoic acid to a 2,4-dioxo-5-hexenoic acid [123] . This extension was conceived as a result of partial superimposition between the cinnamoyl group of various natural and synthetic IN inhibitors ( Figure 18) . One of the highly potent compounds from this series, 66 [123] An additional variation of the DKAs includes a number of dimeric acids, these inhibitors were designed on the hypothesis that two diketo moieties could simultaneously bind to the two divalent metal ions within the IN active-site. As a whole, the dimeric derivatives displayed reduced strandtransfer selectivity and the initial dimeric acids, 67 [112] , 68 [112] , and 69 [112] , displayed limited antiviral activity (Figure 19 ). Figure 20 ) [43] or benzyl 71 [43] linked analogues. Unfortunately, the majority of the amide-linked derivatives were found to be cytotoxic and it is unclear what effects linker geometry has on activity [43] . In contrast, the benzyllinked diketoacids were considerably less toxic, however, the majority displayed minimal anti-viral activity. Unfortunately, the 1,3-diketoacid functionality is biologically labile, giving rise to the derivatives containing diketoacid bioisosteres. A number of diketoacid bioisosteres have been shown to be tolerated on the acid side of the scaffold, these include diketotriazole 45 [106] , diketotetrazole 47 [54] , keto-iminoacid 76 [124] and diketopyridine [125] . However, it appears that the size of the heteroaryl ring is limited as various substituted tetrazole analogues (77, 78, and 79, Figure 23 ) [112] were devoid of activity. A possible explanation for this loss of activity arises from inspection of the 5CITEP co-crystallised structure (Figure 12 ), which infers that the tetrazole ring occupies the relatively polar and confined phosphate-binding pocket [54] . Further, as illustrated by compound 80 (Figure 23 ) [124] , it appears that an optimum distance between diketomimetic atoms must be maintained. 
Naphthyridine IN Inhibitors
In order to mimic the diketoacid motif three functional regions are required, a ketone mimic, an enolisable ketone, and carboxyl oxygen, all of which adopt a coplanar conformation with the aryl portion of the DKA scaffold. Based on this rational, it was hypothesised that a similar arrangement of key hydroxyl groups could be achieved by a 1,2-catechol and by incorporating an oxygen bridge, coplanarity between to two phenyl rings could be achieved (81, Figure 24 ) [126] . Unfortunately, as outlined previously 1,2-catechols are biologically labile producing toxic metabolites, while coplanar polyaromatic ring systems typically exhibit poor physical properties [127] . However, based on previous SAR studies, it was proposed these limitations could be alleviated with the removal of the bridgehead carbon and substitution of one of the catechol hydroxyl groups with an aromatic nitrogen [126] .
Furthermore, it was anticipated that resulting loss of coplanarity could be re-established with the incorporation of a heteroatom at an appropriate position on the aryl ring. These considerations led to the synthesis of a number of potent [1, 6] naphthyridine analogues (82 & 83, Figure 24 ) [126] . Figure 25 ) [128] . Significant improvements in both intrinsic potency and pharmacokinetic properties were obtained with the addition of polar functionalities, such as uracils, amides, and heterocyles, at the 5-position on the naphthyridine backbone [128] . A member of this series, L-870810 85 [129, 28] entered phase I/II clinical trails and although phase II trials were halted due to liver and kidney toxicity another member of this series L-870812 86 [128] is currently still in trials. [131] . It has been demonstrated that the SQs specifically and efficiently inhibit in vitro nuclear import of IN suggesting that they inhibit the interaction between the enzyme and the cellular factor required for its nuclear import [131] . Unlike the PHAs, the catechol moiety of 87 does not induce toxicity nor is its crucial for activity [132] . A substantial amount of SAR data relating to the SQs has been complied [133] [134] [135] [136] 130] and it is evident that numerous aryl moieties such as furan, thiophene, 4-nitrobenzene, and pyridine are well tolerated on the catachol side of the SQ scaffold [132] . In contrast to the catachol portion, variations to the linker functionality are poorly tolerated [133] . Further, as expected, removal [134] , protection [130] or extension [136] of the carboxylic acid functionality was detrimental to activity. An additional variation to the SQ scaffold theme was a series of styrylbenzofuran derivatives [135] , however, these derivatives were considerably less active than their quinoline counterparts. However, a significant increase in activity, and unfortunately cytotoxicity, can be achieved with the introduction of the 3,4,5-trihydroxybenzene moiety [132] , yet, methyl protection of one of these hydroxyls results in the dramatic reduction of cytotoxicity, so much so that compound 88 [132] (FZ-41, Figure 26 ) is poised to enter clinical trials.
More recently, 4-quinolone-3-carboxylic acid was identified as a promising masked diketoacid scaffold. Significant improvements in the antiviral activity of lead compound 89 [127] (Figure 27 ) were achieved with the introduction of 2-fluoro and 3-chloro substituents into the distal benzene ring and alkylation of the quinolone nitrogen with a hydroxyethyl moiety 90 [127] . Further, the introduction of a methoxy group at the 7-position of the quinolone ring of and an isopropyl group at the 1S-position of the hydroxyethyl 91, JTK-303 [127] moiety led to a far more potent inhibitor which is currently under phase I/II clinical trials. The first peptide IN inhibitor isolated from a combinatorial library was the hexapeptide 92 [137] ( Figure 28 ) During an ensuing SAR study of 92, an number of dimer analogues possessing variable linkers, such as L-homolanthionine 93 [138] or L-djenkolic acid 94 [138] , were synthesised. Of these compounds the dithiomethylene linked dimer 94 showed an approximately 20-fold higher potency compared to the monomer indicating that the dimeric peptide may act as a bivalent inhibitor, simultaneously occupying neighbouring catalytic sites. Additional IN peptides include Indolicidin (95, Table 2 ) a tryptophan rich 13-mer natural antibacterial peptide [139, 140] , a 33-mer known as I 33 [141] , and a number of 7-mer derivatives exemplified by 96 and 97 (Table 2 ) which were identified from the random screening of a heptapeptide phage-display library [142] . Recent studies have shown that the catalytic activity of IN is inhibited in vitro by HIV-1 reverse transcriptase (RT) [143] . In a random screen of HIV-1 RT derived peptides two 20-residue-long peptides 98 [143] and 99 [143] were identified as possessing anti-IN activity (Table 3) . and strand transfer activity respectively [144] . More recently, the mimics of all the interfacial secondary structures were synthesised. Although shorter than the initial mimics, the 1 (100 Table 4) [60], and 5 101 [60] derivatives along with -6 mimic 102 [60] displayed potency activity against 3'-processing. Further, protein crosslinking experiments conducted in the presence of the 1, 5, and, 5
indicated the reduced amounts of dimer-core domains were formed indicating that these peptides prevent dimerisation of the IN core domains [60] . Amongst the more potent derivatives were a series of 2-mercaptobenzenesulfonamides (MBSAs), typified by 106 [146] (Figure 30 ). The majority of the MBSAs share a common architecture consisting of aryl units, one of which possesses a 2-mercapto moiety, separated by a sulfonamide-heteroaryl linker. SAR studies of the MBSAs indicated that various hydrophobic functionalities such as butane, were tolerated on the heteroaryl side of the scaffold [146] . Moreover, the introduction of a 4-chlorophenyl amide substituent on the mercaptophenol ring increased activity, however, crucial to activity was the presence of a free mecapto moiety [146] .
Although number of MBSAs displayed potent in vitro activity, they were found to be metabolically unstable. In an attempt to improve stability, a number of cyclic derivatives were produced (107 & 108 Figure 30 ) [147] . Unfortunately, none of the 3-aroyl-1,1-dioxo-1,4,2-benzodithiazines displayed potent activity, however, a number of these derivatives displayed significant differential potencies against the IN mutant C65S, versus the wild type enzyme, suggesting that these compounds potentially interact with C65, which in close proximity to the highly conserved catalytic triad [147] . The lack of potency displayed by the cyclic sulfonamide derivatives is believed to be primarily due to the lack of a free mercaptoaryl group. The mercapto moiety is a well know hydroxy isostere and is present in a number of IN inhibitor such as 109 (figure 31) [100] and the phenyldipyrimidine analogue 110 V-165 [148] which is currently in preclinical trials. As with the cyclic sulfonamides, protection of the free mercapto moieties of 110 yielded an inactive compound (111, Figure 31 ) [148] . In keeping with sulfonamides, sulfone based compounds have a well established safety profile with a number of sulfone derivatives used in the treatment of malaria. A handful of sulfone-based compounds have been identified as IN inhibitors, the most potent being the geminal disulfonates, exemplified by 112 [148] (Figure 32 ) Further, a number of relatively simple diarylsulfones, exemplified by compound 113 [149] were identified in the screen of a National Cancer Institute (NCI) sulfone drug repository. However, a number of diarylsulfones have previously been reported as RT inhibitors, thus giving a possible explanation to their antiviral activity [150] . Despite the potent anti-IN activity of suramin, and the in vivo activity displayed a number of naphthalenesulfonic acid analogues, to date, only a handful of derivatives, such as the moderately active monomers 115 [160] , 116 [160] , (Figure 34 ) and the active derivative 117 (Y3) have been identified as HIV-1 inhibitors. In addition to Y3, two other naphthalenesulfonic acids, 118 (Y1) [161] and 119 (Y2) [161] , were identified using a three-point pharmacophore to screen the NCI three-dimensional database while an additional derivative 120 (Y4) [161] was synthesised in a insuring SAR study of the Y3 series. [161] . However, at present, there is no structural information of any HIV-1 IN-inhibitor complex that binds in this manner.
The Requirement for Second and Third Generation IN Inhibitors
After a decade of research the first-generation IN inhibitors have been patented [164] and are entering clinical trials. However, continual cell-based viral exposure of a number of the most promising inhibitors in cells such as L-870812 has resulted in the emergence of a number of resistant strains [163] . Further, the current generation of IN inhibitors all appear to display similar binding interactions residing within the active-site or dimer interface. Thus, a single mutation within either of these regions may render a whole class of compounds inactive. This observation emphasises the need for the discovery of second and third generation IN inhibitors of novel structure and inhibition mechanisms.
